Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Posts Sharp Decline in Fiscal Q3 Revenue; Re-Evaluating Market, Firm May Miss BACcelr8r Launch Date

The original version of this article incorrectly reported that Accelr8 said in December that it plans to launch its BACceler8r product in fiscal 2006. In fact, the company made this projection in October 2004.

NEW YORK, June 15 (GenomeWeb News) - Accelr8 Technology today reported an 84-percent decline in fiscal third-quarter revenues and a 40-percent rise in net losses, and said it may not launch its BACcelr8r product before the end of July as it had originally promised.

 

Total receipts for the three months ended April 30 declined to $19,800 from $120,104 year over year.

 

Net losses for the period jumped to $788,865, or $.08 per share, from $562,838, or $.06.

 

The company did not disclose its R&D spending in the quarter or break out its balance sheet.

 

In October 2004 Accelr8 said it would begin selling its BACcelr8r product in fiscal 2006, which ends July 31. Asked today whether the company is still following this timeline, President David Howson said "probably not."

 

"We're not sure that the research market is a good place for us to go" with the BACcelr8r, Howson told GenomeWeb News today. He said the company is "currently re-evaluating" the markets in which the product can be sold.

 

The BACcelr8r is designed to provide bacterial identification and antibiotic resistance analysis in "far less time than required by current lab culturing methods," Accelr8 said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.